CYCLIC PENTAMER COMPOUNDS AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDER

The disclosure relates to inhibitors of PCSK9 useful in the treatment of cholesterol lipid metabolism, and other diseases in which PCSK9 plays a role, having the Formula (I):, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, N-oxide, or tautomer thereof, wherein X1, R1, R2, R3, R4, R5, R6, R6', R7, R7', R8, R9, R9', R10, R11, R12, and n are described herein. 本披露涉及有用于治疗胆固醇脂质代谢以及其中PCSK9起作用的其他疾病的PCSK9抑制剂，或其药学上可接受的盐、水合物、溶剂化物、前药、立体异构体、N-氧化物、或互变异构体，所述PCSK9抑制剂具有式(I)，其中X1、R1、R2、R3、R4、R5、R6、R6'、R7、R7'、R8、R9、R9'、R10、R11、R12、和n描述于本文。